An update on familial nonmedullary thyroid cancer

Endocrine. 2020 Jun;68(3):502-507. doi: 10.1007/s12020-020-02250-3. Epub 2020 Mar 11.

Abstract

Familial nonmedullary thyroid cancer (FNMTC) constitutes 3-9% of all thyroid cancer cases. FNMTC is divided into two groups: syndromic and nonsyndromic. Nonsyndromic FNMTC is more common as compared with syndromic FNMTC. In syndromic FNMTC, patients are at risk of nonmedullary thyroid cancer (NMTC) and other tumors, and the susceptibility genes are known. In nonsyndromic FNMTC, NMTC is the major feature of the disease and occurs in isolation with an autosomal dominant pattern of inheritance and variable penetrance. New data have emerged on the genetics, clinical characteristics, and outcomes of patients with FNMTC that may have clinical relevance in the management of patients. In this review, we focus on newly characterized syndromic FNMTC entities, criteria for screening and surveillance of nonsyndromic FNMTC, and the classification of nonsyndromic FNMTC as well as the genetic background and heterogeneity of nonsyndromic FNMTC.

Keywords: Familial; Nonmedullary thyroid cancer; Nonsyndromic; Papillary thyroid cancer; Syndromic.

Publication types

  • Review

MeSH terms

  • Carcinoma, Papillary*
  • Genetic Predisposition to Disease
  • Humans
  • Penetrance
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms* / genetics